Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

Introduction Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory infections worldwide, particularly among newborns, infants, young children, the elderly, and ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s ...

Respiratory Syncytial Virus is a common, contagious virus affecting the lungs and breathing passages.

Health officials are urging older adults to get vaccinated against respiratory syncytial virus (RSV). NHS England announced on Monday that more than one million adults in England, aged between 75 and ...

Respiratory syncytial virus isn’t new, but the spread and severity across the country this season is a concern.

Every year, millions of people worldwide are affected by a virus that often goes unnoticed –Respiratory Syncytial Virus (RSV). Despite its widespread prevalence, many people remain unaware of what RSV ...

What is RSV? Respiratory syncytial virus, or RSV, is a common virus that infects the nose, throat and lungs, according to the U.S. Centers for Disease Control and Prevention. Is it RSV, COVID or the ...

Electron microscope shows human respiratory syncytial virus (RSV) virions, colourised blue, and anti-RSV F protein/gold antibodies, colourised yellow, shedding from the surface of human lung cells ...